Press Releases
Jan 8, 2025

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application...

Jan 8, 2025

- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care...

Jan 5, 2025

- China has the highest number of cases and deaths from gastric cancer of any country worldwide1 - - Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a...

EXPLORE ALL US PRESS RELEASES

Articles
Jul 18, 2024

Diversity, equity and inclusion (DEI) have always been critically important to the Astellas Legal and IP Division. Since 2017, the Astellas Legal and IP Division has actively worked to promote DEI...

Feb 8, 2024

As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during...

Dec 15, 2023

Astellas is proud to be featured on the Human Rights Campaign Foundation’s (HRC) annual Corporate Equality Index (CEI) for its continued support of the LGBTQ+ community within the workplace....

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Download Fact Sheet
Sustainability
Investors
Explore U.S. Products